A new drug treatment to close the window on colon cancer

Jul 21, 2010

Cancer surgery wreaks havoc on a body's immune system and stress hormones exacerbate the problem. As a result, about half of those who undergo surgery for tumor removal experience a recurrence of cancer in the same region or other parts of the body.

A new clinical approach being developed and tested by Tel Aviv University researchers may be the key to making cancer operations more successful. Prof. Shamgar Ben-Eliyahu, head of Tel Aviv University's Department of Psychology, has opened on a new frontier in : he is recruiting patients for a new clinical study which will test a cocktail of drugs to prevent the negative effects of stress responses to surgery. If successful, it will help the immune system maintain its vigor and prevent the occurrence of new tumors.

Prof. Ben-Eliyahu described his method in a recent issue of the .

A more competent immune system

Prof. Ben-Eliyahu and other research teams have confirmed that a competent immune system is critical before, during and after surgery for tumor removal. However, stress responses of the body during this period jeopardize immune competence and facilitate tumor metastasis.

Combining two widely-known medications that affect immune and stress responses, Prof. Ben-Eliyahu has developed a formula he hopes will keep an immune system strong and prevent the recurrence of cancer. Already tested in animal models, the compounds will be employed in a clinical trial in Israel, for which Prof. Ben-Eliyahu's team is currently recruiting patients and funds. They hope to have 800 colon cancer patients participate in the trial, due to begin shortly.

Increasing survival 300%

According to Prof. Ben-Eliyahu, the main that appear to negatively impact immune system functioning are released before and during surgery. He says that existing generic drugs could block the influence of these hormones, helping the body to better fend off the stressors of surgery.

In animal studies, Prof. Ben-Eliyahu found that by blocking these hormones he could increase long-term post-operative survival rates from cancer by as much as 300 percent. If his new study on human volunteers succeeds, it could set a new paradigm for cancer treatment and post-surgery recovery rates. "In rats and mice it works with great success, really beautifully," says Prof. Ben-Eliyahu.

In the upcoming trial, Prof. Ben-Eliyahu will boost patients' immune systems with his drug cocktail over a 20-day period, before, during and after surgery. The two compounds to be used in the study are a beta-adrenergic antagonist, which is used to treat hypertension and anxiety, and a Cyclooxygenase-2 inhibitor, used against inflammation and pain. Since the two drugs are already widely available and routinely used in the clinical setting, no patents need be filed for the application of these drugs.

Explore further: Three-quarters of depressed cancer patients do not receive treatment for depression, new approach could transform care

add to favorites email to friend print save as pdf

Related Stories

Stress and fear can affect cancer's recurrence

Feb 27, 2008

After the surgical removal of a malignant tumor, the chance that cancer will re-appear in a different location of the body remains high. But new research from Tel Aviv University, in a bold new field called Psychoneuroimmunology, ...

Young blood fights cancer

Dec 30, 2008

"New blood" can revitalize a company or a sports team. Recent research by Tel Aviv University finds that young blood does a body good as well, especially when it comes to fighting cancer.

Anti-cancer flower power

Aug 25, 2008

Could a substance from the jasmine flower hold the key to an effective new therapy to treat cancer? Prof. Eliezer Flescher of The Sackler Faculty of Medicine, Tel Aviv University thinks so. He and his colleagues have developed ...

Freezing breast tumors helps stop cancer's spread in mice

Mar 03, 2010

Freezing a cancer kills it in its place, and also appears to generate an immune response that helps stop the cancer's spread, leading to improved survival rates over surgery, according to a new study in mice from researchers ...

New 'bubble' targets only cancer cells

Feb 19, 2009

For millions of Americans with cancer, the side effects of chemotherapy and other treatment drugs can be devastating. But new drug-delivery research based on nano- and microtechnology from Tel Aviv University might provide ...

Recommended for you

Better classification to improve treatments for breast cancer

7 hours ago

Breast cancer can be classified into ten different subtypes, and scientists have developed a tool to identify which is which. The research, published in the journal Genome Biology, could improve treatments and targeting of tre ...

Risk of diabetes up in hodgkin's lymphoma survivors

9 hours ago

(HealthDay)—Para-aortic radiation correlates with increased diabetes mellitus (DM) risk for Hodgkin's lymphoma (HL) survivors, according to a study published online Aug. 25 in the Journal of Clinical On ...

User comments : 0